

# ORA-Blend<sup>®</sup> SF

## Flavoured Sugar-Free Oral Suspending Vehicle

ORA-Blend SF is a flavoured sugar-free oral suspending vehicle used to simplify the process involved in the extemporaneous compounding of oral suspensions. Medicated powder can be incorporated into ORA-Blend SF to form elegant, uniform and physically stable suspensions.

Product code	PDE Code	Size
ORA03316F	191299	473 mL



### Applications

ORA-Blend SF combines the suspending properties of ORA-Plus<sup>®</sup> with the flavouring agents of ORA-Sweet<sup>®</sup> SF and is ideal for:

- Pediatric suspensions
- Geriatric suspensions

### Properties

ORA-Blend SF is an aqueous-based sweetened vehicle consisting of a synergistic blend of suspending agents that have a high degree of colloidal activity. The suspending agents form a structured, gel-like matrix which suspends particles and allow for little settling. ORA-Blend SF is buffered to a slightly acidic pH to help reduce degradation of medicinal agents through oxidation. An anti-foam agent is incorporated in ORA-Blend SF to allow for vigorous shaking with minimal foam.

### Ingredients

Purified water, sorbitol, glycerin, flavouring, microcrystalline cellulose, carboxymethylcellulose sodium, xanthan gum, carrageenan, calcium sulfate, trisodium phosphate, and sodium saccharin, sodium phosphate, citric acid and sodium citrate as buffers, dimethicone antifoam emulsion. Preserved with methylparaben, potassium sorbate, and propylparaben.

### Specifications

**Appearance:** Opaque, pinkish liquid

**pH:** Approximately 4.2

**Taste:** Sweet citrus-berry flavour

**Viscosity:** Approximately 1000 cps at 25°C via Brookfield viscometer

**Osmolality:** 1073 mOsm/kg

**Order today through your wholesaler**

# ORA-Blend® SF

## Formulating & Compounding Examples

### LAMOTRIGINE 1 mg/mL, 100 mL<sup>1</sup>

Lamotrigine 100 mg/tablet 1 tablet  
ORA-Blend SF q.s. 100 mL

- Expiration 91 days at 4°C and 25°C
- Protect from light
- Shake well before using

### SPIRONOLACTONE 5 mg/mL, plus HYDROCHLOROTHIAZIDE 5 mg/mL, 120 mL<sup>3</sup>

Spirolactone-Hydrochlorothiazide 25 mg/25 mg/tablet 24 tablets  
ORA-Blend SF q.s. 120 mL

- Expiration 60 days at 5°C and 25°C
- Protect from light
- Shake well before using

### RIFAMPIN 25 mg/mL, 120 mL<sup>2</sup>

Rifampin 300 mg/capsules 10 capsules  
ORA-Blend SF q.s. 120 mL

- Expiration 28 days at 5°C and 25°C
- Protect from light
- Shake well before using

### VERAPAMIL HYDROCHLORIDE 50 mg/mL, 120 mL<sup>3</sup>

Verapamil HCl 80 mg/tablet 75 tablets  
ORA-Blend SF q.s. 120 mL

- Expiration 60 days at 5°C and 25°C
- Protect from light
- Shake well before using

### General Directions for Compounding ORA-Blend SF Suspensions

- Calculate the total amount of active ingredient and volume of solution needed to create a suspension of the proper concentration. (Calculations are provided in the examples to the left.) *It may be wise to add approximately 10% overage for compounding losses.*
- Crush tablets with a mortar and pestle to a fine powder. If the compound is already in the powder form, use the mortar and pestle to smooth out the powder.
- Add a small amount of ORA-Blend SF and triturate to a thick, smooth paste. Add the remainder of the ORA-Blend SF by geometric dilution.
- Mix briefly with a mortar and pestle until a uniform suspension is formed.
- Dispense in a tight, light resistant amber bottle with appropriate labeling.
- Label with an expiration date. *If the stability of the medication in an oral suspension or syrup is unknown, conservative dating is suggested.*
- Depending on the medicinal agent used, label containers "Shake Well Before Using", "Protect From Light", and "Keep Refrigerated".

<sup>1</sup>American Journal of Health-System Pharmacists 1999; 56:240-2.

<sup>2</sup>American Journal of Health-System Pharmacists 1998; 55:1804-9.

<sup>3</sup>American Journal of Health-System Pharmacists 1996; 53:2304-2309.



### Contraindications

ORA-Blend SF is contraindicated in persons who have shown hypersensitivity to any of the listed ingredients.

All information presented is intended to demonstrate the application of Perrigo vehicles in compounding. Perrigo products are sold on the understanding that purchasers will make their own determinations as to the suitability, safety and effectiveness of their applications. The uses presented by Perrigo are only to assist our customers in exploring possible applications.

All information and data presented are believed to be accurate and reliable, but are presented without the assumption of any liability by Perrigo Pharmaceuticals. Perrigo Pharmaceuticals does not warrant against infringements of patents of third parties by reason of any uses made of the vehicles in combination with other material or in the operation of any process, and purchasers assume all risks of patent infringement by reason of any such use, combination or operation.